Author: Branwen Brockley
-
Sir Shankar Balasubramanian elected Fellow of the AACR Academy
Sir Shankar has been recognised for his pioneering research in nucleic acid chemistry and his key role in the development of next-generation sequencing technology.
Find out more -
Richard Mair joins Institute as an Independent Clinical Fellow
Richard will build a research group at the Institute to focus on IDH mutant astrocytoma, , a common type of brain tumour that accounts for 9% of brain tumour diagnoses.
Find out more -
Imaging technique allows rapid assessment of ovarian cancer subtypes and their response to treatment
An MRI-based imaging technique developed at the Institute predicts the response of ovarian cancer tumours to treatment, and rapidly reveals how well treatment is working, in patient-derived cell models.
Find out more -
Isabel Esain Garcia awarded PhD Thesis Prize
The Prize is awarded annually to a student who has undertaken an outstanding research project to the highest standards during the course of their PhD study at the Cancer Research UK Cambridge Institute.
Find out more -
World first trial to revolutionise treatment of brain cancer
A pioneering research study will trial multiple new treatments for people in the UK living with glioblastoma, an aggressive form of brain cancer.
Find out more -
Institute receives unprecedented £173M commitment from CRUK
Cancer Research UK has announced a £173 million investment in the Cambridge Institute - the largest single grant ever awarded by the charity outside of London.
Find out more -
Madzia Crossley appointed as Junior Group Leader
Dr Magdalena (Madzia) Crossley will be joining the Cancer Research UK Cambridge Institute as a Junior Group Leader starting in early 2025.
Find out more -
Cambridge children’s cancer scientists to share £3M boost
Cambridge researchers are set to receive a major cash injection from Cancer Research UK to help develop the next generation of treatments for children with brain tumours.
Find out more -
Scientists awarded £5m to advance groundbreaking tumour mapping technology
The IMAXT team have been awarded £5.2 million to establish the Spatial Profiling and Annotation Centre of Excellence (SPACE) to open up access to their groundbreaking cancer mapping technology to the research field.
Find out more